WEILL MEDCL COLL is a pharmaceutical company focused on Oncology, Neurology.
WEILL MEDCL COLL's Key Drugs
WEILL MEDCL COLL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
WEILL MEDCL COLL's Recent FDA Approvals
New NDA/BLA approvals for WEILL MEDCL COLL over the last two years — novel drugs only, excluding generics and label supplements.
WEILL MEDCL COLL's Therapeutic Areas
WEILL MEDCL COLL's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
WEILL MEDCL COLL's Top Competitors
WEILL MEDCL COLL's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
WEILL MEDCL COLL Pipeline Snapshot
Active clinical trials for WEILL MEDCL COLL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2004-08-05
- Latest
- 2006-12-21
- Applications
- 1